Fate Therapeutics, Inc.
FATE Healthcare Biotechnology
Fate Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 million, down 51.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.18%, EPS grew 13.8% and free cash flow grew 8.96%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow FATE
Fate Therapeutics, Inc. (FATE) P/E ratio
Fate Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 41 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| FATE Fate Therapeutics, Inc. | n/m |
| KROS Keros Therapeutics, Inc. compare | n/m |
| GLSI Greenwich LifeSciences, Inc. compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| IMRX Immuneering Corporation compare | n/m |
| SLGL Sol-Gel Technologies Ltd. compare | n/m |
| QTTB Q32 Bio Inc. compare | 2.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)